Understanding CLIM2 functions in vivo using transgenic RNAi
Understanding CLIM2 functions in vivo using transgenic RNAi
批准号:
7472089
负责人:
ZUOSHANG XU
金额:
$20.43万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-15 至 2010-05-31
关键词:
AffinityBindingBrainCell Differentiation processCellsCodeDNA Polymerase IIDNA Polymerase IIIDevelopmentDiseaseDisease modelEmbryoEmbryonic DevelopmentEstrogen receptor positiveEukaryotaEukaryotic CellExposure toFunctional disorderGene ExpressionGene SilencingGene TargetingGenesGoalsHumanInvestigationKnock-outKnockout MiceLIM DomainLengthMalignant NeoplasmsMammalsMammary NeoplasmsMediatingMethodsMicroRNAsModelingMusOncogene ProteinsOutcomePathway interactionsPatternPhenotypePlayProcessPublic HealthRNARNA InterferenceResearch PersonnelRoleSequence HomologySiteSmall Interfering RNATechnologyTestingThinkingTimeTissuesTransgenesTransgenic MiceTransgenic OrganismsUbiquitin CUntranslated RegionsWorkage relatedbasecell typecofactorcostdevelopmental diseaseexpression vectorgene functionhomeodomainin vivoknockout genemalignant breast neoplasmmouse modelneurogenesispositional cloningpre-miRNApromoterrecombinaseresearch studysmall hairpin RNAsuccesstranscription factorvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Gene knockout technology in mice has been instrumental in investigating gene functions in mammals. It has been used to reveal gene functions in normal as well as in pathogenic pathways in vivo, and to generate disease models including models of many age-dependent diseases. However, the technical complexity, the length of time and the high cost of gene knockout approach has limited its wider use. This has slowed the analysis of gene functions in mammals. Recent experiments have demonstrated that transgenic RNAi can be a simpler, faster and more economical alternative for reverse genetics in mammals. We propose to test a more sophisticated transgenic RNAi strategy that will give investigator more control over where and when to induce gene silencing. We will test a construct that is driven by a ubiquitously active promoter, which synthesizes EGFP initially. This allows easy screen of transgenic lines that carry and express the transgene. The EGFP coding sequence is flanked with loxP site. Therefore, after exposure to Cre recombinase it will be excised, permitting the promoter to synthesize RFP and a pre-miRNA, which is placed in the 3'-UTR. The pre-miRNA can be processed in cells to form miRNA and mediate gene silencing. We propose to use this construct to express a miRNA that silences CLIM2 (cofactor of LIM homeodomain transcription factors, also known as Ldb1 or NLI), which is a cofactor of LIM homeodomain transcription factors (LIM-HD) and LIM-only oncoproteins (LMO). CLIM2 plays important roles in cell differentiation and patterning during development and is thought to play a role in cancer. However, functional studies of CLIM2 have been hampered by the early embryonic lethality of the knockout mice. Because gene silencing will be inducible spatially and temporally, our approach, if successful, will enable us to investigate the function of CLIM2 in cell differentiation, brain developmental patterning and cancer in detail. PUBLIC HEALTH RELEVANCE We will use a new method, transgenic RNAi, to determine CLIM2 gene functions in mammals. Compared with the existing method, the new method will be simpler, cheaper, faster and more flexible. If successful, our method will generate a mouse model for CLIM2 dysfunction, which will allow investigation into the role of CLIM2 in development and in cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS
-
批准号:10399654
-
项目类别:
-
资助金额:$48.77万
-
财政年份:2021
-
负责人:ZUOSHANG XU
-
依托单位:
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS
-
批准号:10605239
-
项目类别:
-
资助金额:$48.77万
-
财政年份:2021
-
负责人:ZUOSHANG XU
-
依托单位:
Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS
-
批准号:10298171
-
项目类别:
-
资助金额:$48.77万
-
财政年份:2021
-
负责人:ZUOSHANG XU
-
依托单位:
A new approach to immunotherapy for ALS
-
批准号:9808031
-
项目类别:
-
资助金额:$46.06万
-
财政年份:2019
-
负责人:ZUOSHANG XU
-
依托单位:
An in vivo approach to understanding mutant PFN1 toxicity on motor neurons
-
批准号:9893934
-
项目类别:
-
资助金额:$36.64万
-
财政年份:2017
-
负责人:ZUOSHANG XU
-
依托单位:
A new approach to modeling ALS based on TBK1 mutation in mice
-
批准号:9275555
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2016
-
负责人:ZUOSHANG XU
-
依托单位:
Does TDP-43 dysfunction in astrocytes trigger motor neuron degeneration?
-
批准号:9110354
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2015
-
负责人:ZUOSHANG XU
-
依托单位:
Modeling Mutant Profilin 1 Toxicity and ALS in vivo
-
批准号:8490556
-
项目类别:
-
资助金额:$20.8万
-
财政年份:2013
-
负责人:ZUOSHANG XU
-
依托单位:
Transgenic models of ALS caused by VAPB mutation
-
批准号:8055338
-
项目类别:
-
资助金额:$34.84万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Transgenic models of ALS caused by VAPB mutation
-
批准号:7567500
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Transgenic models of ALS caused by VAPB mutation
-
批准号:7799908
-
项目类别:
-
资助金额:$35.19万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Transgenic models of ALS caused by VAPB mutation
-
批准号:8265853
-
项目类别:
-
资助金额:$34.84万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Transgenic models of ALS caused by VAPB mutation
-
批准号:7466543
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Modeling TDP-43 Dysfunction in vivo
-
批准号:7451906
-
项目类别:
-
资助金额:$17.77万
-
财政年份:2008
-
负责人:ZUOSHANG XU
-
依托单位:
Modeling Progranulin hypomorphism for FTD in mice
-
批准号:7362633
-
项目类别:
-
资助金额:$17.77万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Modeling Progranulin hypomorphism for FTD in mice
-
批准号:7495557
-
项目类别:
-
资助金额:$21.33万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Silencing mutant SOD1 in vivo for treatment of ALS
-
批准号:7247798
-
项目类别:
-
资助金额:$22.82万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Reverse genetics using RNAi in non-mouse mammals
-
批准号:7343224
-
项目类别:
-
资助金额:$19.59万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Reverse genetics using RNAi in non-mouse mammals
-
批准号:7212491
-
项目类别:
-
资助金额:$16.66万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
Silencing mutant SOD1 in vivo for treatment of ALS
-
批准号:7385006
-
项目类别:
-
资助金额:$17.84万
-
财政年份:2007
-
负责人:ZUOSHANG XU
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: